Skip to main content

Market Overview

Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices


In a report published Friday, Jefferies analyst Jeffrey Holford named AbbVie Inc (NASDAQ: ABBV) as a "Top Global Pick" in the Pharmaceutical space, replacing Pfizer Inc. (NYSE: PFE).

Holford added that shares have seen significant pressure since mid-December as the initial guidance for Viekira Pak "disappointed" and concerns over Humira's durability re-emerged and that the defenses for Humira have "purposefully been kept hidden." Despite that, the analyst said that he sees a "great entry point" into AbbVie given "a very strong set of drivers" and "iceberg" of good news to emerge in the first half of 2015 as updates from the company are expected on both fronts.

"We are more confident than ever that the durability of Humira will outlast current market expectations following our recent meeting with Rick Gonzalez, CEO of AbbVie," Holford wrote. "We also see strong underlying data to support above-consensus estimates for Viekira Pak. Last, our recent meeting with CSO, Mike Severino, also helped us to more fully understand the potential of both the emerging early to mid-stage pipeline as well as the more visible late stage R&D assets."

Alternative Top Picks

Holford also listed Pfizer, Roche Holding Ltd., AstraZeneca plc (NYSE: AZN) Bayer AG as top picks.

Least Preferred List

Holford named Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Co (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK) as "least preferred" stocks.

Latest Ratings for ABBV

Feb 2021SVB LeerinkMaintainsOutperform
Jan 2021Morgan StanleyMaintainsOverweight
Dec 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings


Related Articles (PFE + ABBV)

View Comments and Join the Discussion!

Posted-In: Bayer AG Humira Jefferies Jeffrey HolfordAnalyst Color Health Care Analyst Ratings General

Latest Ratings

IRIXRoth CapitalMaintains9.0
AMRSRoth CapitalMaintains33.0
VORBarclaysInitiates Coverage On56.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at